Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TCBP - TC BioPharm (Holdings) plc

1.78
-0.170   -9.551%

Share volume: 163,453
Last Updated: 03-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.02%

PREVIOUS CLOSE
CHG
CHG%
$1.95
-0.17
-0.09%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-8.72%
1 Month
-44.72%
3 Months
204.22%
6 Months
-66.54%
1 Year
4.09%
2 Year
-99.71%
Key data
Stock price
$1.78
P/E Ratio 
0.00
DAY RANGE
$1.77 - $1.95
EPS 
N/A
52 WEEK RANGE
$0.20 - $9.43
52 WEEK CHANGE
-$1.11
MARKET CAP 
2.888 M
YIELD 
N/A
SHARES OUTSTANDING 
518.463 K
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-10-2025
NEXT EARNINGS DATE
N/A
BETA 
-1.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$600,189
AVERAGE 30 VOLUME 
$673,948
Company detail
CEO: Bryan Kobel
Region: US
Website: tcbiopharm.com
Employees: 80
IPO year: 2022
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

TC Biopharm (Holdings) Plc focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia.

Recent news